Indication
Astrocytoma
42 clinical trials
56 products
12 drugs
Product
dabrafenibClinical trial
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)Status: Recruiting, Estimated PCD: 2026-05-29
Product
trametinibClinical trial
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)Status: Completed, Estimated PCD: 2021-08-23
Product
VincristineProduct
OKN-007Clinical trial
A Phase 1b Open-Label Study Investigating the Tolerability, Safety, and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade GliomaStatus: Recruiting, Estimated PCD: 2024-05-15
Product
DabrafenibProduct
CarboplatinProduct
Low-dose OKN-007Clinical trial
A Phase 1, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics and Central Nervous System (CNS) Penetration of CC-90010 in Preoperative Subjects With Progressive or Recurrent Who Grade II Diffuse Astrocytoma, Grade III Anaplastic Astrocytoma and Recurrent Glioblastoma Scheduled for ResectionStatus: Active (not recruiting), Estimated PCD: 2024-05-09
Product
CC-90010Clinical trial
Phase 2 Study of Olutasidenib With Temozolomide as Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 MutationsStatus: Not yet recruiting, Estimated PCD: 2029-06-01
Product
OlutasidenibProduct
High-dose OKN-007Product
BMX-001Product
TemozolomideClinical trial
A Phase 2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001Status: Active (not recruiting), Estimated PCD: 2023-08-17
Clinical trial
A Phase Ib/2 Open-label Study Investigating the Tolerability, Safety, Pharmacokinetic Properties and Efficacy of Oral OKN-007 in Participants With Recurrent High-grade GliomaStatus: Withdrawn, Estimated PCD: 2025-04-01
Clinical trial
A Phase I/IIa Open Label Multicenter, Non-Randomized, Trial to Assess the Safety and Efficacy of CYNK-001in Combination With Recombinant Human Interleukin-2 in Adults With Recurrent Resection Eligible IDH1 Wild-type GlioblastomaStatus: Withdrawn, Estimated PCD: 2024-02-01
Product
CYNK-001Clinical trial
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV GliomaStatus: Completed, Estimated PCD: 2011-03-01
Product
QBS10072SClinical trial
A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 AstrocytomaStatus: Completed, Estimated PCD: 2022-09-21
Product
Systemic TreatmentClinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)Status: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma: Study Protocol for An International Multicenter Prospective Cohort Study (ENCRAM 2302)Status: Recruiting, Estimated PCD: 2027-01-01
Product
TMZProduct
LomustineClinical trial
Phase I Study of Replication-Competent Adenovirus-Mediated Double Suicide Gene Therapy With Stereotactic Radiosurgery in Patients With Recurrent or Progressive High Grade AstrocytomasStatus: Recruiting, Estimated PCD: 2024-10-01
Product
Ad5-yCD/mutTKSR39rep-ADPClinical trial
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem GliomaStatus: Active (not recruiting), Estimated PCD: 2023-09-30
Product
APX005MClinical trial
ATTAC-II: A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Patients With Newly-Diagnosed GlioblastomaStatus: Completed, Estimated PCD: 2023-11-30
Product
pp65-shLAMP DC with GM-CSFProduct
unpulsed PBMC and salineClinical trial
tGLI1 as a Therapeutic Target in Brain Metastases: A Window of Opportunity Study in Breast Cancer Brain Metastases and Primary GliomasStatus: Recruiting, Estimated PCD: 2024-07-01
Product
KetoconazoleProduct
TdProduct
SalineProduct
pp65-flLAMP DCClinical trial
A Phase 2 Trial of All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant GliomaStatus: Recruiting, Estimated PCD: 2026-06-01
Product
RetifanlimabClinical trial
A Pilot Study of Safety, Tolerability, and Immunological Effects of SurVaxM in Pediatric Patients With Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine GliomaStatus: Recruiting, Estimated PCD: 2025-08-30
Product
SurVaxMProduct
All-trans retinoic acidClinical trial
A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade GliomasStatus: Completed, Estimated PCD: 2023-06-30
Drug
AtezolizumabProduct
VorinostatClinical trial
Phase I/II Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination With Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma MultiformeStatus: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Phase I Study of the Adam-10 Inhibitor, INCB7839 in Children With Recurrent/Progressive High-Grade Gliomas to Target Microenvironmental Neuroligin-3Status: Active (not recruiting), Estimated PCD: 2023-12-31
Product
INCB7839Clinical trial
A Phase 1, Safety Lead-In and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination With Pembrolizumab in Subjects With Recurrent or Progressive Enhancing IDH-1 Mutant GliomaStatus: Recruiting, Estimated PCD: 2025-03-31
Product
VorasidenibDrug
mFOLFOX6Clinical trial
Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent GlioblastomaStatus: Completed, Estimated PCD: 2022-08-15
Product
LB-100Product
PembrolizumabClinical trial
Pilot Randomized Neo-adjuvant Evaluation of Poly-ICLC-Assisted Tumor Lysate Vaccines in Adult Patients With WHO Grade II GliomaStatus: Active (not recruiting), Estimated PCD: 2022-08-15
Product
GBM6-ADClinical trial
A Phase I Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2, a Genetically Engineered HSV-1 Virus, and Immunomodulation With CyclophosphamideStatus: Recruiting, Estimated PCD: 2024-12-01
Product
rQNestinDrug
cyclophosphamideClinical trial
Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic GliomaStatus: Recruiting, Estimated PCD: 2024-12-01
Product
QPOPClinical trial
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 GliomaStatus: , Estimated PCD: 2025-05-31
Drug
LurbinectedinDrug
T-VECClinical trial
Pilot Randomized Neo-adjuvant Evaluation of Agonist Anti-CD27 Monoclonal Antibody Varlilumab on Immunologic Activities of IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)Status: Active (not recruiting), Estimated PCD: 2022-12-31
Product
IMA950Product
poly-ICLCDrug
VarlilumabClinical trial
A Phase 2 Investigator Initiated Study to Determine the Efficacy and Safety of TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade AstrocytomaStatus: Completed, Estimated PCD: 2020-04-04
Product
TVB-2640Clinical trial
Phase 1 Study of Replication Competent Reovirus (Reolysin®) in Combination With GM-CSF in Pediatric Patients With Relapsed or Refractory Brain TumorsStatus: Completed, Estimated PCD: 2018-07-13
Drug
GM-CSFProduct
Wild-type ReovirusClinical trial
Pilot Study to Evaluate the Safety, Tolerability and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma (Phase I)Status: Completed, Estimated PCD: 2022-09-21
Clinical trial
A Phase 1/2 Open-label Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed GlioblastomaStatus: Recruiting, Estimated PCD: 2028-09-01
Product
Debio 0123Clinical trial
Phase I-II Study Evaluating HSV-tk + Valacyclovir Gene Therapy Combination With Radiotherapy and Chemotherapy for Recurrent Glioblastoma MultiformeStatus: Recruiting, Estimated PCD: 2023-12-30
Product
ADV/HSV-tkClinical trial
Phase 0/I Dose Escalation Study of Mycophenolate Mofetil Combined With Radiation Therapy in GlioblastomaStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Evaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-specific Dendritic Cell Vaccines With Adjuvant TEtanus Pre-conditioning in Patients With Newly-diagnosed GlioblastomaStatus: Completed, Estimated PCD: 2020-10-31
Clinical trial
A Phase I Study of Mebendazole for the Treatment of Pediatric GliomasStatus: Recruiting, Estimated PCD: 2024-04-01
Product
MebendazoleDrug
VincristineDrug
AN0025Clinical trial
A Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Primary Brain TumorsStatus: Recruiting, Estimated PCD: 2023-09-21
Product
MicrodeviceClinical trial
A Phase II Randomized Controlled Trial for the Addition of Chloroquine, an Autophagy Inhibitor, to Concurrent Chemoradiation for Newly Diagnosed GlioblastomaStatus: Withdrawn, Estimated PCD: 2023-11-10
Product
ChloroquineClinical trial
A Phase IB Study to Use Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV AstrocytomaStatus: Completed, Estimated PCD: 2023-06-07
Product
TadalafilDrug
mFOLFOXIRIProduct
Unpulsed DCsProduct
111In-labeled DCsProduct
BasiliximabClinical trial
A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain TumorsStatus: Recruiting, Estimated PCD: 2030-08-31
Drug
R-CHOPProduct
EtoposideClinical trial
A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic AstrocytomaStatus: Active (not recruiting), Estimated PCD: 2024-12-05
Product
TelaglenastatClinical trial
Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain TumorsStatus: Active (not recruiting), Estimated PCD: 2025-09-01
Product
G207